Vivos Therapeutics (VVOS) announced that its VidaSleep oral appliance, featuring Vivos’ patented and U.S. Food and Drug Administration, FDA, cleared Unilateral Bite Block technology, has been approved by the Centers for Medicare & Medicaid Services, CMS, Pricing, Data Analysis and Coding, PDAC, contractor for the treatment of mild to moderate OSA and snoring in adults.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VVOS:
- Vivos announces results published of OSA using Daytime-Nighttime Appliance
- Vivos Therapeutics Acquires The Sleep Center of Nevada
- Vivos Therapeutics completes acquisition of SCN for $6M in cash, $1.5M in stock
- Vivos Therapeutics Secures $1.1M Convertible Note
- Vivos Therapeutics downgraded to Neutral from Buy at Alliance Global Partners